Early access program for zolbetuximab in stomach cancer
Treatments studied
Part of Cancer clinical trials.
This early access program offers the investigational drug zolbetuximab for people with advanced stomach cancer that has a specific protein marker. The study aims to make this targeted treatment available before it is fully approved, potentially helping those who have limited options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stomach cancer or cancer at the gastroesophageal junction that has spread and cannot be removed by surgery.
- Your tumor must have a specific protein marker (CLDN18.2) in at least 75% of the cancer cells.
- Your tumor must be HER2-negative (a genetic test result).
- You are in fairly good health (able to do daily activities) and have adequate blood counts and organ function.
- You have not had chemotherapy for advanced disease before; however, you may have had chemo or radiation after surgery if it was over 6 months ago.
- You are not pregnant and are willing to avoid pregnancy or sperm donation during the treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called zolbetuximab added to standard chemotherapy for people with advanced stomach or gastroesophageal junction cancer. It may help slow the cancer's growth.
This study looks at how well zolbetuximab works when combined with chemotherapy in people with advanced stomach or gastroesophageal junction cancer. It aims to help doctors understand the best ways to use this treatment in everyday practice.
This trial tests a new combination of drugs (zolbetuximab, pembrolizumab, and chemotherapy) for people with advanced stomach or gastroesophageal junction cancer. It may be an option if your tumor has certain proteins (CLDN18.2 and PD-L1) and you haven't had chemotherapy for advanced disease.
This trial is looking at a drug called zolbetuximab, given with chemotherapy, for people with a certain type of stomach or gastroesophageal junction cancer that has spread and has high levels of a protein called claudin 18.2. The goal is to see how well it works in real-world settings.
This trial is for people with advanced stomach cancer that has a specific protein called Claudin18.2 and is HER2-negative. It tests whether continuing zolbetuximab—a drug that targets this protein—can help control the cancer.
This trial tests a combination of three drugs (zolbetuximab, paclitaxel, and ramucirumab) for people with advanced stomach or esophagus cancer that has a specific protein called CLDN18.2. It may be an option if you've already had one standard treatment.
Hear when a new Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.